

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
27 December 2002 (27.12.2002)

PCT

(10) International Publication Number  
**WO 02/102822 A1**

(51) International Patent Classification<sup>7</sup>: **C07H 19/16**,  
A61K 31/7076, A61P 9/00

(21) International Application Number: PCT/GB02/02841

(22) International Filing Date: 19 June 2002 (19.06.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0115178.6 20 June 2001 (20.06.2001) GB

(71) Applicant (*for all designated States except US*): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **KING, Paula** [GB/GB]; GlaxoSmithKline, Park Road, Ware, Hertfordshire SG12 0NY (GB).

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



**WO 02/102822 A1**

(54) Title: ADENOSINE DERIVATIVE IN POLYMORPH II FORM


(57) Abstract: (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form.



## ADENOSINE DERIVATIVE IN POLYMORPH II FORM

The present invention relates to heterocyclyl substituted adenosine derivatives. More particularly the invention is concerned with a particular physical form of (2S,3S,4R,5R)-2-(5-tert-butyl-  
 5 [1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-  
 diol, pharmaceutical formulations thereof and its use in therapy.

WO99/67262 (Glaxo Group Limited) discloses certain heterocyclyl adenosine derivatives including (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-  
 10 fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol, Example 14 of WO99/67262, the structure of which is indicated below as the compound of formula (A):



(A)

15 The preparation of the compound of formula (A) is described in WO99/67262. The compound of formula (A) may be prepared by the reaction of 4-chloro-2-fluoroaniline with an appropriate purinyl derivative having a suitable leaving group in the 6-position of the purine ring, optionally in the presence of a solvent at elevated temperatures. Alternatively the compound of formula (A) may be prepared by treating 9-((3aR,4R,6S,6aR)-6-[5-tert-butyl-1,3,4-oxadiazol-2-yl]-2,2-  
 20 dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-N-(4-chloro-2-fluorophenyl)-9H-purin-6-amine with trifluoroacetic acid followed by treatment with sodium bicarbonate. Extraction of the product into ethyl acetate followed by evaporation *in vacuo* provides the compound of formula (A) as a buff solid.

25 We have now surprisingly found that the compound of formula (A) can be obtained in polymorphic form.

There is thus provided as a first aspect of the invention (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in  
 30 polymorphic form.

We have further found that the compound of formula (A) may also be crystallised in the form of polymorphic form II (hereinafter Polymorph II).

There is thus provided in a yet further aspect of the invention (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol as Polymorph II.

Polymorph II exhibits particular stability at elevated temperatures, for example temperatures in excess of 70°C.

Polymorph II may be useful in the preparation of pharmaceutical formulations which may involve temperatures above ambient temperatures.

In a preferred aspect the invention provides (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph II as herein defined substantially free of impurities.

In a further preferred aspect the invention (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph II as herein defined substantially free of alternative polymorphs.

By "substantially free" is meant containing less than 10%, preferably less than 5%, more preferably less than 2%, of alternative polymorph or impurity.

(2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol may be prepared in polymorphic form by crystallisation of the compound under suitable conditions.

Polymorph II may be prepared substantially free from other polymorphs by controlling crystallisation conditions.

In general, (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in the form of Polymorph II may be obtained by crystallisation of the compound by heating in methyl isobutyl ketone at reflux (117-118°C) and allowing to cool to ambient temperature, for example 15- 25°C.

Polymorph II may also be prepared by dissolving (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in methyl isobutyl ketone at reflux, filtering, concentrating the filtrate, cooling to 45-70°C, preferably 50-55°C and collecting Polymorph II by filtration.

- Alternatively Polymorph II is prepared by dissolving (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in N,N-dimethylformamide and water wherein the N,N-dimethylformamide:water ratio is from 2:1 to 1:2, optionally treating with decolourising charcoal, adjusting the temperature to greater than 35°C, and optionally seeding with polymorph II. Optionally, toluene may be added prior to collecting the resulting solid.

Interconversion of one polymorph to another can occur under certain circumstances.

- The methods for the preparation of polymorphic material, and in particular methods for the preparation of Polymorph II, described herein constitute further aspects of the present invention.

Polymorph II has been characterised by X-ray powder diffraction (XRPD) studies and Raman spectroscopy.

- Polymorph II is characterised by having peaks in its Raman spectra at 3424, 1615 and 92 cm<sup>-1</sup>.

Raman peaks are quoted to the nearest cm<sup>-1</sup>.

- Polymorph II is characterised by having an XRPD pattern with signals at 4.74, 5.34, 6.63, 7.87, 8.31, 8.93, 10.71, and 13.98 (degrees 2-theta).

- The skilled person will recognise that XRPD peak positions are affected by differences in sample height. The peak positions quoted herein are thus subject to a variation of +/- 0.15 degrees 2-theta.

- This invention further provides for a pharmaceutical composition comprising (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form, and a pharmaceutically acceptable carrier and/or excipient.

Suitable pharmaceutically acceptable carriers and excipients are described in WO 99/967262.

- (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form may be used for decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea, as described in WO 99/67262.

- (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form may be used in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea, as described in WO 99/67262.

WO 99/67262 (Glaxo Group Limited) is incorporated by reference herein as though fully set forth.

- 5 The following examples illustrate the invention but are not intended as a limitation thereof.

### EXAMPLES

- 10 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol was prepared according to the methods described in WO99/67262.

#### Example 1 - Preparation of Polymorph II

- 15 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol (10g) was taken up in methyl isobutyl ketone (MIBK, 170mL) and the mixture heated to reflux to effect dissolution. The solution was then cooled to ambient over *ca.* 30 mins (crystallisation commenced at *ca.* 70°C) and the thick slurry stirred for a  
20 further hour. The matted crystals were then filtered off, washed with cold MIBK (1x15mL) and dried *in vacuo* at 60°C. Yield: 83%.

#### Example 2 - Preparation of Polymorph II

- 25 (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol (165.8g) was dissolved in MIBK (3800mL) at reflux. The resulting solution was filtered and the filter washed with MIBK (415mL). The combined filtrate and wash were re-heated to reflux and MIBK (1520mL) was removed by distillation under reduced pressure. The residue was cooled to 50°C and the product was collected by filtration,  
30 washed with MIBK and then dried *in vacuo* at 40°C to give Polymorph II as an off white solid (130.9g, 75% recovery).

### X-Ray Powder Diffraction

- 35 The sample preparation and acquisition conditions were as follows:

Samples were lightly ground and packed into silicon cup with a 12 mm (diameter) x 0.5 mm cavity. Data were acquired using a Bruker D8 Advance X-Ray diffractometer configured with a Cu anode, primary and secondary Soller slits, secondary monochromator and scintillation  
40 counter. The generator was operated at 40 kV 40 mA. Variable divergence and antiscatter slits were set at 12 mm irradiated area, and the detector slit was set at 0.1 mm. A locked coupled step scan with 0.02 degrees 2 -theta step was used. The sample was rotated.

Data obtained for Polymorph II are shown in Figure 1.

### **Raman Spectroscopy**

5 Raman spectra were acquired using a Nicolet 960 ESP FT-Raman spectrometer. Samples were held in glass vials; spectra of 5 different points on a sample were averaged. Data collection parameters include: Laser power: 400 mW, Resolution: 4 cm<sup>-1</sup>, Sample gain: 1.0, Detector: InGaAs, Beamsplitter: CaF<sub>2</sub>, Correction: none, Zero filling: none, Apodization: Happ-Genzel, Phase correction: Power spectrum.

10

A Raman spectrum of Polymorphs II is shown in Figure 2.

A photographic image of Polymorph II is shown in Figure 3.

15 The application of which this description and these claims form a part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features relating to the invention described herein. They may take the form of product, process or use claims and may include, by way of example and without limitation, the claims that follow.

20

25

30

35

40

## CLAIMS

1. (2S,3S,4R,5R)-2-(5-tert-Butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form.
- 5 2. A polymorphic form according to claim 1 wherein the polymorphic form is Polymorph II.
3. A pharmaceutical formulation comprising a polymorphic form according to claim 1 or claim 2, and a pharmaceutically acceptable carrier and/or excipient.
- 10 4. A polymorphic form according to to claim 1 or claim 2 for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea.
- 15 5. Use of a polymorphic form according to to claim 1 or claim 2 in the manufacture of a medicament for use in decreasing plasma free fatty acid concentration; reducing heart rate; or treating ischemic heart disease, peripheral vascular disease, stroke, pain, CNS disorder, or sleep apnoea.
- 20 6. (2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran-3,4-diol in polymorphic form substantially as described herein in the specification and/or examples.

Figure 1

## X-RAY DIFFRACTION DATA

## 5 Polymorph II

GW493838 1A05584 DB100065-003A1







Figure 2

## RAMAN SPECTRA


5

## Polymorph II



**Figure 3**

PHOTOGRAPHIC IMAGE OF POLYMORPH II



5

Form II MIBK

## INTERNATIONAL SEARCH REPORT

In: ational Application No  
PCT/GB 02/02841A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07H19/16 A61K31/7076 A61P9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07H A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 67262 A (BAYS DAVID EDMUND ; COUSINS RICHARD PETER CHARLES (GB); JUDKINS BRI) 29 December 1999 (1999-12-29) cited in the application page 1 page 122-123, example 14 -----	1-6



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&amp;\* document member of the same patent family

Date of the actual completion of the international search

10 September 2002

Date of mailing of the international search report

17/09/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

de Nooy, A

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/02841

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9967262	A	29-12-1999	
		AU 4514699 A	10-01-2000
		BG 105155 A	28-09-2001
		BR 9911498 A	20-03-2001
		CN 1314910 T	26-09-2001
		EE 200000784 A	15-04-2002
		WO 9967262 A1	29-12-1999
		EP 1090019 A1	11-04-2001
		HR 20000896 A1	31-12-2001
		JP 2002518509 T	25-06-2002
		NO 20006520 A	14-02-2001
		PL 345089 A1	03-12-2001
		SK 19582000 A3	06-11-2001
		TR 200100449 T2	21-08-2001